Symbol not found
:CELG
0.00
0.00
(0.00%)
Celgene Corporation (NASDAQ:CELG) Beats Earnings
Celgene Corporation (NASDAQ:CELG) Earnings
Date Published: 7-28-2016Author: Ophir Gottlieb
Preface
Celgene Corporation (NASDAQ:CELG) released earnings this morning before the open and the company beat Wall Street estimates. The stock is up smartly on the day.
EARNINGS
Celgene Corporation reported $1.44 in earnings per share versus street estimates of $1.39. Further, Celgene reported $2.75 billion in revenue versus estimates of $2.70 billion. The company also raised guidance for full year 2016, projecting EPS in a tight range of $5.70 to $5.75, up from prior guidance of $5.60 to $5.70. Remember, Celgene Corporation updated its guidance all the way out to the year 2020, forecasting $21 billion in revenue and EPS of $13.
BEYOND THE HEADLINES
Here is what Celgene Corporation (NASDAQ:CELG) disclosed in its press release and earnings call:
Revlimid sales for the second quarter increased 18% year-over-year to $1,701 million and were driven by new patient market share gains and increased duration. U.S. sales of $1,080 million and international sales of $621 million increased 24 percent and 9% year-over-year, respectively.
Pomalyst/Imnovid sales for the second quarter were $318 million, an increase of 35% year-over-year. U.S. sales were $185 million and international sales were $133 million, an increase of 29% and 46% year-over-year, respectively. Pomalyst/Imnovid sales grew due to increased volume from duration gains.
Abraxane sales for the second quarter were $249 million, a 2% increase year-over-year. U.S. sales of $175 million increased 3% year-over-year. International sales were $74 million. Otezla sales for the second quarter were $242 million, a 170% increase year-over-year. U.S. sales were $217 million and international sales were $25 million. Sales were driven by market share gains and increased prescriber adoption.
In the second quarter, all other product sales, which include Thalomid, Istodax, Vidaza and an authorized generic version of Vidaza drug product in the U.S., were $235 million compared to $242 million in the second quarter of 2015.
BEYOND THE DETAILS
Taking a step backwards, we can see that Celgene Corporation is a marvel. It has a rich pipeline, the most successful oncology drug in the world and a handful of partnerships that pose little risk to the firm but enormous potential upside for future earnings.
Here is how Celgene's internal pipeline looks relative to the rest of large cap biotechnology:
The chart above plots the number of Phase II trials for each of the biotechnology and pharmaceutical companies with market caps above $5 billion. We can see that Celgene Corporation (NASDAQ:CELG) has the most, tied with pharma giant Pfizer Inc. (NYSE:PFE).
But, there's actually a lot more going on with Celgene, too much to cover in one news post.
WHY THIS MATTERS
Celgene is one of just eight spotlight Top Picks for CML Pro. We identify trends and companies that allows us to find the 'next Apple' or the 'next Google.' This is what CML Pro does. Our research sits side-by-side with Goldman Sachs, Morgan Stanley and the rest on professional terminals, but we are the anti-institution and break the information advantage the top .1% have.
Each company in our 'Top Picks' is the single winner in an exploding thematic shift like artificial intelligence, Internet of Things, drones, biotech and more. In fact, here are just two of the trends that will radically affect the future that we are ahead of:
That chart plots the growth in 4G usages worldwide and how it will grow from 330 million people today to nearly 2 billion in five years. This is the lifeblood fueling every IoT and mobile device on the planet and CML Pro has named the single winner that will power this transformation. Then there's cyber security:
Market correction or not, recession or not, the growth in this area is a near certainty, even if projections come down, this is happening. CML Pro has named the single best cyber security stock to benefit from this theme.
These are just two of the themes we have identified and this is just one of the fantastic reports CML Pro members get along with all the visual tools, the precious few thematic top picks for 2016, research dossiers and alerts. For a limited time we are offering CML Pro at a 90% discount for $10/mo. with a lifetime guaranteed rate. Join Us: Get the most advanced premium research delivered to your inbox along with access to visual tools and data that until now has only been made available to the top 1%.